{"id":"extended-postimplantation-dual-antiplatelet-therapy","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Bleeding (major and minor)"},{"rate":"1-3","effect":"Gastrointestinal bleeding"},{"rate":"0.5-1","effect":"Intracranial hemorrhage"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dual antiplatelet therapy (DAPT) combines two agents that work synergistically to prevent blood clots: aspirin irreversibly inhibits cyclooxygenase and thromboxane A2 production, while P2Y12 inhibitors (clopidogrel, prasugrel, or ticagrelor) block adenosine diphosphate-mediated platelet activation. Extended DAPT beyond the standard 12 months aims to reduce late stent thrombosis and recurrent ischemic events in high-risk patients, though it increases bleeding risk.","oneSentence":"Extended dual antiplatelet therapy (typically aspirin plus a P2Y12 inhibitor) prevents stent thrombosis and reduces cardiovascular events by inhibiting platelet aggregation for a prolonged period after coronary stent implantation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:46:09.731Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of stent thrombosis and recurrent ischemic events after percutaneous coronary intervention with stent implantation in high-risk patients"}]},"trialDetails":[{"nctId":"NCT05660811","phase":"PHASE4","title":"Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure in Dialyzed Patients","status":"RECRUITING","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2022-09-28","conditions":"Atrial Fibrillation","enrollment":80},{"nctId":"NCT03445949","phase":"PHASE4","title":"Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure","status":"RECRUITING","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2018-01-23","conditions":"Atrial Fibrillation","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"extended postimplantation dual antiplatelet therapy","genericName":"extended postimplantation dual antiplatelet therapy","companyName":"National Institute of Cardiology, Warsaw, Poland","companyId":"national-institute-of-cardiology-warsaw-poland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Extended dual antiplatelet therapy (typically aspirin plus a P2Y12 inhibitor) prevents stent thrombosis and reduces cardiovascular events by inhibiting platelet aggregation for a prolonged period after coronary stent implantation. Used for Prevention of stent thrombosis and recurrent ischemic events after percutaneous coronary intervention with stent implantation in high-risk patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}